A photoreceptor state links aggressive brain tumors in children

Stefan M Pfister1, Lena M Kutscher2

  • 1Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany; German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Division of Pediatric Neurooncology, Heidelberg, Germany; Heidelberg University Hospital, Department of Pediatric Hematology and Oncology, Heidelberg, Germany; National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg, Germany.

Cancer Cell
|March 20, 2026
PubMed

Insights

Group 3 medulloblastoma, pineoblastoma, and retinoblastoma share a photoreceptor signature from developmental cells. This finding suggests a common vulnerability and potential therapeutic targets for these rare pediatric cancers.

Area of Science:

  • Pediatric oncology
  • Developmental biology
  • Cancer genetics

Background:

  • Medulloblastoma, pineoblastoma, and retinoblastoma are aggressive pediatric brain tumors.
  • These distinct tumor types arise during early development.
  • Understanding their shared origins is crucial for therapeutic advancement.

Purpose of the Study:

  • To investigate the molecular underpinnings of Group 3 medulloblastoma, pineoblastoma, and retinoblastoma.
  • To identify common developmental pathways and transcriptional dependencies across these malignancies.
  • To explore potential shared therapeutic vulnerabilities.

Main Methods:

  • Comparative genomic and transcriptomic analysis of tumor samples.
  • Analysis of developmental progenitor cell populations.
  • Bioinformatic identification of shared molecular signatures.

Main Results:

  • Group 3 medulloblastoma, pineoblastoma, and retinoblastoma exhibit a convergent, shared tumor-associated photoreceptor gene expression signature.
  • This signature is linked to transient developmental progenitor cells.
  • Shared transcriptional dependencies were identified across these tumor types.

Conclusions:

  • These rare pediatric cancers share a common developmental vulnerability rooted in photoreceptor development.
  • The identified shared molecular features offer potential therapeutic targets.
  • Reframing these malignancies based on common developmental origins may guide future treatment strategies.